# A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Study · id `cardio:ct-nct02906917` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02906917](<https://clinicaltrials.gov/study/NCT02906917>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02906917

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 532 participants.

## Technical summary

Registry record NCT02906917. Randomized; no masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2017-08-31 (actual). Results posted on 2018-09-28.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 532 participants (enrolled count; ClinicalTrials.gov record NCT02906917, source copy `cardio:ctgov-nct02906917-2019-11-13`, retrieved 2026-10-26)
- Started: 2016-09-20 (actual) (ClinicalTrials.gov record NCT02906917, source copy `cardio:ctgov-nct02906917-2019-11-13`, retrieved 2026-10-26)
- Primary completion: 2017-08-31 (actual) (ClinicalTrials.gov record NCT02906917, source copy `cardio:ctgov-nct02906917-2019-11-13`, retrieved 2026-10-26)
- Completion: 2017-12-24 (actual) (ClinicalTrials.gov record NCT02906917, source copy `cardio:ctgov-nct02906917-2019-11-13`, retrieved 2026-10-26)
- Results first posted: 2018-09-28 (ClinicalTrials.gov record NCT02906917, source copy `cardio:ctgov-nct02906917-2019-11-13`, retrieved 2026-10-26)
- Countries: United States; Algeria; Czechia; India; Russia; Serbia; Türkiye (ClinicalTrials.gov record NCT02906917, source copy `cardio:ctgov-nct02906917-2019-11-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02906917-2019-11-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Insulin degludec/insulin aspart
- Intervention (Drug): Insulin glargine
- Intervention (Drug): Insulin aspart
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus (`cardio:pubmed-30448451`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9047bfbaaf06f3c48c5d71ba0f09e2597e9f0039b4eb2caf4f921e3c1b7fe015
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
